Renaissance Technologies
CRBP icon

Renaissance Technologies’s Corbus Pharmaceuticals CRBP Stock Holding History

Renaissance Technologies’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Sell
110,822
-236,176
-68% -$2.24M ﹤0.01% 2291
2026
Q1 		$3.26M Sell
346,998
-7,302
-2% -$61.5K 0.01% 1619
2025
Q4 		$2.88M Buy
354,300
+247,100
+231% +$3.05M ﹤0.01% 1648
2025
Q3 		$1.36M Sell
107,200
-46,339
-30% -$441K ﹤0.01% 2323
2025
Q2 		$1.06M Sell
153,539
-191,661
-56% -$1.39M ﹤0.01% 2490
2025
Q1 		$1.83M Buy
345,200
+206,100
+148% +$1.82M ﹤0.01% 2060
2024
Q4 		$1.64M Buy
139,100
+123,100
+769% +$2.06M ﹤0.01% 2176
2024
Q3 		$330K Buy
+16,000
New +$819K ﹤0.01% 2945
2024
Q2 		– Sell
-10,123
Closed -$397K – 3557
2024
Q1 		$397K Buy
+10,123
New +$250K ﹤0.01% 2965
2023
Q1 		– Sell
-3,423
Closed -$11K – 4029
2022
Q4 		$11K Sell
3,423
-22,928
-87% -$88.2K ﹤0.01% 4029
2022
Q3 		$130K Sell
26,351
-27,878
-51% -$197K ﹤0.01% 3510
2022
Q2 		$410K Buy
54,229
+15,656
+41% +$151K ﹤0.01% 3274
2022
Q1 		$615K Buy
38,573
+30,383
+371% +$403K ﹤0.01% 3049
2021
Q4 		$151K Buy
+8,190
New +$222K ﹤0.01% 3603
2021
Q1 		– Sell
-32,070
Closed -$1.2M – 3365
2020
Q4 		$1.2M Buy
32,070
+832
+3% +$31.1K ﹤0.01% 2412
2020
Q3 		$1.69M Buy
31,238
+24,851
+389% +$4.5M ﹤0.01% 2235
2020
Q2 		$1.61M Buy
+6,387
New +$1.29M ﹤0.01% 2300
2018
Q3 		– Sell
-5,561
Closed -$842K – 3369
2018
Q2 		$842K Buy
+5,561
New +$1.01M ﹤0.01% 2664
2016
Q4 		– Sell
-6,307
Closed -$1.28M – 3271
2016
Q3 		$1.28M Buy
6,307
+1,410
+29% +$175K ﹤0.01% 2437
2016
Q2 		$439K Buy
4,897
+3,010
+160% +$236K ﹤0.01% 2840
2016
Q1 		$102K Buy
1,887
+1,094
+138% +$48.3K ﹤0.01% 3210
2015
Q4 		$39K Buy
+793
New +$40.4K ﹤0.01% 3197

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Renaissance Technologies's CRBP Position: Q2 2026 in Review

Renaissance Technologies reduced its Corbus Pharmaceuticals (CRBP) stake by 68% in Q2 2026, selling an estimated $2.24M and leaving 110,822 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2291.

Renaissance Technologies first reported a position in CRBP in Q4 2015 and has held it in 22 quarters since. The position peaked at $3.26M in Q1 2026. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Renaissance Technologies held 110,822 shares of Corbus Pharmaceuticals worth $1.04M as of Q2 2026.
  • Renaissance Technologies sold 236,176 Corbus Pharmaceuticals shares in Q2 2026, an estimated $2.24M.
  • Corbus Pharmaceuticals made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2291 holding.
  • Renaissance Technologies first reported a position in Corbus Pharmaceuticals in Q4 2015 and has held it in 22 quarters since.
  • Renaissance Technologies's Corbus Pharmaceuticals position peaked at $3.26M in Q1 2026.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.